Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03503799 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Study acronym: RESCUE
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv11
  2. Site details revised at 1 of 40 sitesv10
  3. Re-verified, no change to tracked fieldsv9
  4. Primary and study completion dates: May 1, 2031 to Oct 1, 2032
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 1200 to confirmed 1191
    • Study sites: 46 to 40
    v8
  5. Study sites: 44 to 46v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 37 to 44v6
  2. Re-verified, no change to tracked fieldsv5
  3. Study sites: 14 to 37v4
  4. Study sites: 2 to 14
    • Eligibility criteria revised
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of May 1, 2018 to Jul 17, 2018
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.
Trial Details
NCT Number NCT03503799
Lead Sponsor North Eastern German Society of Gynaecological Oncology
Collaborators: Philipps University Marburg
Conditions
(from sponsor)		 Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor
Related terms Breast Neoplasms
Enrollment 1,191 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov